Integra LifeSciences (NASDAQ:IART) Coverage Initiated at UBS Group

Investment analysts at UBS Group assumed coverage on shares of Integra LifeSciences (NASDAQ:IART) in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm set a “neutral” rating and a $19.00 price target on the life sciences company’s stock. UBS Group’s price objective indicates a potential downside of 2.71% from the stock’s previous close.

A number of other brokerages also recently issued reports on IART. Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Wells Fargo & Company boosted their price target on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Citigroup restated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Truist Financial raised their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $18.43.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $19.53 on Tuesday. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.40. The firm has a fifty day simple moving average of $17.50 and a 200 day simple moving average of $13.36. The company has a market capitalization of $1.52 billion, a PE ratio of -3.02, a P/E/G ratio of 1.37 and a beta of 1.22. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter in the prior year, the firm posted $0.41 earnings per share. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP lifted its position in Integra LifeSciences by 1.3% in the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after acquiring an additional 100,000 shares in the last quarter. Paradigm Capital Management Inc. NY raised its stake in shares of Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Integra LifeSciences by 0.9% in the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Integra LifeSciences by 9.2% during the third quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after buying an additional 267,134 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Integra LifeSciences by 0.8% during the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after buying an additional 21,717 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.